linjc16/ctgov huggingface dataset:
Swallowing Characteristics of Pediatric Patients With Eosinophilic Esophagitis

Study Overview
=================
Brief Summary
-----------------
Eosinophilic Esophagitis (EoE) can affect patients all age group and clinical symptoms of the disease varies depending on the patient's ages. Infants and toddlers with EoE generally have food refusal, vomiting and poor weight gain. Older school-aged children and adolescents may have abdominal and chest pain, difficulty in swallowing (dysphagia) especially in solid foods. In the meantime, many children especially infants and toddlers, are not perceptive of their dysphagia, because they have the ability to compensate. Such as, avoiding certain textures or increases liquid intake in the meal.To date, to our knowledge, there is no study in the literature has investigated complex swallowing behaviour (including all phases), oral-motor evaluation and/or swallowing safety. Thus, the present study purposed to investigate (a) descriptive and clinical swallowing characteristics of children with EoE (b) the relation between disease characteristic and swallowing function.

Official Title
-----------------
Clinical Characteristics of Swallowing in Pediatric Patients With Eosinophilic Esophagitis

Conditions
-----------------
Eosinophilic Esophagitis

Intervention / Treatment
-----------------
* Diagnostic Test: Swallowing Evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children and adolescents aged 2-17 years with a diagnosis of Eosinophilic Esophagitis Exclusion Criteria: Do not accommodate the study Do not want to attempt the study

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Swallowing Evaluation|Study Evaluation includes basic test batteries. These are observational.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mastication and Observation Evaluation | Each child was positioned in an upright sitting position in a quiet environment. A standardized biscuit was offered in front of their mouth to bite and chew. Chewing performance of each child was scored according to the T-MOE by observing the child. | 15 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pediatric version of the Eating Assessment Tool-10 | The PEDI-EAT-10 is a parent report outcome instrument to determine penetration and aspiration risk in children. | 10 minutes |
Comparative Study of Postprocessing Imaging Systems for Diminutive Colonic Polyps

Study Overview
=================
Brief Summary
-----------------
Several novel imaging technologies are currently used for detection and differentiation of colonic polyps during colonoscopy, such as NBI (Olympus), FICE (Fujinon), and i-Scan (Pentax). Several previous studies have indicated that NBI without magnification can be useful for real-time differentiation of diminutive colonic neoplasias. To date, however, there are no studies comparing NBI with other imaging systems (FICE or i-Scan) for differentiation of diminutive colonic polyps. The study objectives are to compare the diagnostic efficacy of NBI with that of i-Scan in real-time prediction of diminutive colonic polyps. In this prospective pilot study, diminutive colonic polyps detected during colonoscopy will be observed with conventional colonoscopy, thereafter will be observed with new imaging systems. Sensitivity, specificity, and diagnostic accuracy of both NBI and i-Scan will be assessed by reference to histological results obtained by endoscopic biopsy or polypectomy.

Official Title
-----------------
Prospective Comparison of NBI and i-Scan in Real-time Histological Prediction of Diminutive Colonic Polyps

Conditions
-----------------
Diminutive Colon Polyp, Adenomatous Polyp, Hyperplastic Polyp, Colonoscopy

Intervention / Treatment
-----------------
* Other: Observation using NBI system
* Other: Observation using i-Scan system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: screening or surveillance colonoscopy age over 18 informed consent Exclusion Criteria: history of inflammatory bowel diseases history of hereditary colorectal cancers and polyposis syndrome inability to give informed consent use of antiplatelet agent and anticoagulants pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NBI observation<br> | Other: Observation using NBI system<br>* NBI system can improve the patterns of mucosal surface and vascularity of colonic polyp.<br>* Other names: NBI, narrow band imaging (Olympus, Japan);|
| Experimental: i-Scan observation<br> | Other: Observation using i-Scan system<br>* I-Scan system can improve the patterns of mucosal surface and vascularity of colonic polyp.<br>* Other names: i-Scan (Pentax, Japan);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic efficacy | Sensitivity, specificity, and diagnostic accuracy | about 1 year |
Improvement of Hemostasis Techniques After Median Sternotomy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare 2 different hemostatic agents (Bonewax and Ostene)to a control group with regards to bleeding, bone healing, pain and infection in a patient group all undergoing median sternotomy.

Official Title
-----------------
Improvement of Hemostasis Techniques After Median Sternotomy

Conditions
-----------------
Sternal Dehiscence, Sternal Infection, Sternal Pain

Intervention / Treatment
-----------------
* Device: Ostene
* Device: Bonewax


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: men undergoing elective cardiac surgery at the Cardiac surgery department of Aarhus University Hospital, Skejby no clopidogrel-treatment no osteoporoses less than 2 co-morbidities in the form of obesity (BMI>30), COPD, chronic steroid use, renal failure, immunosuppression and diabetes Exclusion Criteria: profuse sternal bleeding serious complications to the surgery fx cerebral infarction re-operation due to bleeding

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br> | |
| Active Comparator: Bonewax<br>Patients treated with the hemostatic bonewax | Device: Bonewax<br>* applied to sternal surface<br>|
| Active Comparator: Ostene<br>Patients treated with the hemostatic Ostene | Device: Ostene<br>* applied to sternal surface<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone healing in sternum |  | 6 months after surgery | 
| Questionnaire regarding physical and emotional well being |  | 6 months after surgery | 
| Pain-score (VAS) |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood product consumption |  | 6 months | 
| Mediastinitis |  | 6 months | 
| superficial infection |  | 6 months | 
| Bleeding through the chest tube |  | 6 months |
Pleth Variability Index and Fluid Management During Surgery

Study Overview
=================
Brief Summary
-----------------
Pleth Variability Index (PVI) seems to be an ideal parameter to guide fluid management: dynamic parameter and non-invasive. PVI could guide fluid management during surgery and optimization of the plethysmographic-derived parameter could improve hemodynamics of the patients.

Official Title
-----------------
Is Pleth Variability Index Able to Guide Fluid Management During Surgery?

Conditions
-----------------
Fluid Management

Intervention / Treatment
-----------------
* Other: PVI-guided fluid management


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major abdominal surgery Exclusion Criteria: Refusal or inability to understand the protocol Arrythmia <18 years Contraindication to normal mechanical ventilation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PVI<br>PVI guided fluid management | Other: PVI-guided fluid management<br>* Peroperative comparison of standard care with PVI-guided fluid management (optimization of the PVI value with fluid loading)<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemodynamics and derived-parameters |  | The first 48 h | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All causes of morbi-mortality |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pleth variability Index, Fluid management, Fluid management during surgery
The Effectiveness of Idazoxan in Treating TRD

Study Overview
=================
Brief Summary
-----------------
Assessing the effectiveness of Idazoxan as a treatment for depressive patients who did not respond to treatment with SSRI

Conditions
-----------------
Major Depressive Disorder

Intervention / Treatment
-----------------
* Drug: Idazoxan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: MDD patients Did not respond to at least one treatment of 4-6 weeks of SSRI in adequate dose In or out patients Exclusion Criteria: Psychotic symptoms

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Idazoxan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Low Fructose Diet in Diabetes Type 2

Study Overview
=================
Brief Summary
-----------------
Diabetes is one of the most common and chronic diseases in the world, with the prevalence and incidence of this disease rising in most societies, especially in Iran. Suitable treatments for type 2 diabetes include changing lifestyle with exercise, nutrition, and drug use. New research suggests that added sugar, especially fructose, is the main trigger for diabetes and pre-diabetes even more potent than other carbohydrates. Fructose has a low glycemic index (23μg =) and slowly increases blood glucose levels. Therefore, it is thought that replacing fructose instead of glucose can have a positive effect on glycemic control of diabetic patients..

Official Title
-----------------
Effects of Low Fructose Diet on Glycemic Control in Patients With Type 2 Diabetes

Conditions
-----------------
Fructose Metabolism Disorder

Intervention / Treatment
-----------------
* Other: low frutose diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age of 70-40 years body mass index(BMI) between 18.5 and 27 Type 2 diabetes People who only control their diabetes by using glucose lowering tablets Type 2 diabetes (1 to 10 years) Exclusion Criteria: Pregnancy and lactation Thyroid gland disorders Kidney disease and inflammation Follow the weight loss regimen 6 months before starting the study Usage of fatty and fatty foods, fiber powder Vitamin A Mineral Supplements, Omega 3 Taking glucocorticoid drugs and non-steroidal anti-inflammatory drugs

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: intervention group<br>Eight weeks of low fructose diet with a maximum of 12 g of fructose | Other: low frutose diet<br> <br> |
| No Intervention: control group<br>Eight weeks of regular diabetic diet with a 15%pro 30%fat 55%CHO | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fasting blood suger(FBS) |  | 8 weeks | 
| Homeostatic model assessment and insulin resistance(HOMA-IR) |  | 8weeks | 
| insulin |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Triglyceride |  | 8 weeks | 
| Total cholestrole |  | 8 weeks | 
| LDL-C |  | 8 weeks | 
| HDL-C |  | 8 weeks | 
| Blood pressure |  | 8 weeks |
Survey on the Effectiveness of the PLAB Examination in Continuing Clinical Education in British Doctors.

Study Overview
=================
Brief Summary
-----------------
Online survey for all international medical graduate doctors who decided to get a job in the UK; they must do GMC registration.

Official Title
-----------------
Survey the Effectiveness of PLAB Examination in Further Clinical Training in the United Kingdom

Conditions
-----------------
International Medical Graduate Student

Intervention / Treatment
-----------------
* Other: non interventional


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Post-PLAB exam and GMC registration international medical graduate Candidates who practise in NHS as FY1 and FY2 Exclusion Criteria: Pass PLAB one exam Pass PLAB two exam Candidates pass PLAB one and two but still not working in NHS
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: non interventional|Online google form questioner|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cross section online google form questioner | cross section online google form questioner | 1 month |
Respiratory Mechanics Assessment During Assisted Mechanical Ventilation

Study Overview
=================
Brief Summary
-----------------
To verify the association between respiratory system mechanical properties (ΔP, ΔPL,dyn, Pmus, Pplat and CRS and CL,dyn) assessed during assisted modes of ventilation (as average over the first three days since enrollment) and ICU mortality.

Official Title
-----------------
ICEBERG STUDY. Respiratory Mechanics Assessment During Assisted Mechanical Ventilation

Conditions
-----------------
Acute Hypoxemic Respiratory Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute Hypoxaemic Respiratory Failure (defined as respiratory failure requiring invasive mechanical ventilation with a PaO2/FiO2< 300 mmHg) during the course of ICU stay (including ARDS). Invasive mechanical ventilation in one of these modes: Pressure A/C, PRVC, SIMV PC, PSV, NAVA, PAV+, BiPAP Presence of spontaneous breathing activity (ventilator triggering), since 6 hours and no longer than 48 hours Patient for full active management at this point. Exclusion Criteria: Age <18 years old Pregnancy Active air leaks Moribund state High ICP Patient has passed a spontaneous breathing trial (if performed for clinical indication) Known COPD with history of home oxygen therapy and/or non invasive ventilation and/or GOLD III-IV. Non invasive ventilation for sleep apnea is NOT an exclusion criteria.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between respiratory system mechanical properties and ICU mortality | Difference between mean values of driving pressure in survivors and non-survivors at ICU discharge. | 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between respiratory system compliance and ICU mortality | Difference between mean values of respiratory system compliance in survivors and non-survivors at ICU discharge. | 90 days | 
| Correlation between plateau pressure and ICU mortality | Difference between mean values of plateau pressure in survivors and non-survivors at ICU discharge. | 90 days | 
| Correlation between pressure muscle index and ICU mortality | Difference between mean values of pressure muscle index (PMI) in survivors and non-survivors at ICU discharge. | 90 days | 
| Correlation between muscle pressure and ICU mortality | Difference between mean values of muscle pressure (Pmus) in survivors and non-survivors at ICU discharge. | 90 days |
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Inhaled TPI 1100 in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
This study will look at the safety and tolerability of TPI 1100 in healthy volunteers and look at pharmacodynamic (PD) effect on mRNA expression of PDE 4B/D & 7A in blood and in sputum.

Detailed Description
-----------------
Study was not initiated and terminated before start-up.

Official Title
-----------------
A Phase 1,Randomized, Double--blind, Placebo-controlled Study Assessing the Safety and Tolerability, the Pharmacodynamics and Pharmacokinetics of Single-ascending and Repeated Doses of Inhaled TPI 1100 in Healthy Subjects

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Drug: TPI 1100


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy, male or female volunteers aged 18 to 55 years inclusive Screening/baseline FEV1 greater than 90% predicted, Body mass index (BMI) of 19 to 28 inclusive, Clinical laboratory values and/or vital signs within normal reference ranges or not considered clinically significant by the Investigator Exclusion Criteria: Airways or systemic conditions that might affect respiratory function, including but not limited to clinically significant cardiac problems, Breast-feeding or pregnancy, Positive tests for smoking tobacco, alcohol, hepatitis B-surface antigen, hepatitis C antibody, and HIV at screening, History of serious adverse reaction to any drugs,

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TPI 1100<br>Drug to be given by inhalation. | Drug: TPI 1100<br>* 1 dose only increasing dose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Airway-specific and general safety and tolerability. |  | 24 hours post-dose and on Day 4 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect on mRNA |  | 24 hrs post-dose and on Day 4 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD